Screener
UroGen Pharma URGN PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 12,776 | 14,672 |
| Total current assets | 235,426 | 186,024 |
| Non-current assets: | ||
| Property and equipment, net | 597 | 637 |
| Restricted deposit | 178 | 177 |
| Finance lease right-of-use assets | 4,818 | 5,376 |
| Operating lease right-of-use assets | 2,810 | 3,080 |
| Other non-current assets | 8,761 | 5,161 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's PP&E (net)?
- UroGen Pharma (URGN) reported PP&E (net) of $597K in Q2 2026.
- How has UroGen Pharma's PP&E (net) changed year-over-year?
- UroGen Pharma's PP&E (net) decreased by 13.2% year-over-year, from $688K to $597K.
- What is the long-term trend for UroGen Pharma's PP&E (net)?
- Over 5 years (2020 to 2025), UroGen Pharma's PP&E (net) has grown at a -20.8% compound annual growth rate (CAGR), from $2.05M to $637K.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about UroGen Pharma's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude